vs

Side-by-side financial comparison of Emerson Electric (EMR) and NXP Semiconductors (NXPI). Click either name above to swap in a different company.

Emerson Electric is the larger business by last-quarter revenue ($4.3B vs $3.2B, roughly 1.4× NXP Semiconductors). NXP Semiconductors runs the higher net margin — 35.3% vs 13.9%, a 21.4% gap on every dollar of revenue. On growth, Emerson Electric posted the faster year-over-year revenue change (4.1% vs -5.0%). NXP Semiconductors produced more free cash flow last quarter ($714.0M vs $602.0M). Over the past eight quarters, NXP Semiconductors's revenue compounded faster (0.9% CAGR vs -0.3%).

Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.

NXP Semiconductors N.V. is a Dutch semiconductor manufacturing and design company with headquarters in Eindhoven, Netherlands. It is the third largest European semiconductor company by market capitalization as of 2024. The company employs approximately 34,000 people in more than 30 countries and it reported revenues of $12.61 billion in 2024.

EMR vs NXPI — Head-to-Head

Bigger by revenue
EMR
EMR
1.4× larger
EMR
$4.3B
$3.2B
NXPI
Growing faster (revenue YoY)
EMR
EMR
+9.1% gap
EMR
4.1%
-5.0%
NXPI
Higher net margin
NXPI
NXPI
21.4% more per $
NXPI
35.3%
13.9%
EMR
More free cash flow
NXPI
NXPI
$112.0M more FCF
NXPI
$714.0M
$602.0M
EMR
Faster 2-yr revenue CAGR
NXPI
NXPI
Annualised
NXPI
0.9%
-0.3%
EMR

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
EMR
EMR
NXPI
NXPI
Revenue
$4.3B
$3.2B
Net Profit
$605.0M
$1.1B
Gross Margin
53.2%
59.5%
Operating Margin
17.8%
100.0%
Net Margin
13.9%
35.3%
Revenue YoY
4.1%
-5.0%
Net Profit YoY
3.4%
147.0%
EPS (diluted)
$1.07
$4.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EMR
EMR
NXPI
NXPI
Q1 26
$3.2B
Q4 25
$4.3B
$3.3B
Q3 25
$4.9B
$3.2B
Q2 25
$4.6B
$2.9B
Q1 25
$4.4B
$2.8B
Q4 24
$4.2B
$3.1B
Q3 24
$4.6B
$3.3B
Q2 24
$4.4B
$3.1B
Net Profit
EMR
EMR
NXPI
NXPI
Q1 26
$1.1B
Q4 25
$605.0M
$455.0M
Q3 25
$637.0M
$631.0M
Q2 25
$586.0M
$445.0M
Q1 25
$485.0M
$490.0M
Q4 24
$585.0M
$495.0M
Q3 24
$996.0M
$718.0M
Q2 24
$329.0M
$658.0M
Gross Margin
EMR
EMR
NXPI
NXPI
Q1 26
59.5%
Q4 25
53.2%
54.2%
Q3 25
51.9%
56.3%
Q2 25
52.6%
53.4%
Q1 25
53.5%
55.0%
Q4 24
53.5%
53.9%
Q3 24
51.3%
57.4%
Q2 24
52.8%
57.3%
Operating Margin
EMR
EMR
NXPI
NXPI
Q1 26
100.0%
Q4 25
17.8%
22.3%
Q3 25
16.4%
28.1%
Q2 25
16.1%
23.5%
Q1 25
14.2%
25.5%
Q4 24
18.6%
21.7%
Q3 24
14.7%
30.5%
Q2 24
10.4%
28.7%
Net Margin
EMR
EMR
NXPI
NXPI
Q1 26
35.3%
Q4 25
13.9%
13.6%
Q3 25
13.1%
19.9%
Q2 25
12.9%
15.2%
Q1 25
10.9%
17.3%
Q4 24
14.0%
15.9%
Q3 24
21.6%
22.1%
Q2 24
7.5%
21.0%
EPS (diluted)
EMR
EMR
NXPI
NXPI
Q1 26
$4.43
Q4 25
$1.07
$1.80
Q3 25
$1.12
$2.48
Q2 25
$1.04
$1.75
Q1 25
$0.86
$1.92
Q4 24
$1.02
$1.93
Q3 24
$1.74
$2.79
Q2 24
$0.57
$2.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EMR
EMR
NXPI
NXPI
Cash + ST InvestmentsLiquidity on hand
$3.7B
Total DebtLower is stronger
$7.6B
$11.7B
Stockholders' EquityBook value
$20.3B
$10.9B
Total Assets
$41.9B
$27.1B
Debt / EquityLower = less leverage
0.37×
1.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EMR
EMR
NXPI
NXPI
Q1 26
$3.7B
Q4 25
$3.3B
Q3 25
$3.5B
Q2 25
$3.2B
Q1 25
$4.0B
Q4 24
$3.3B
Q3 24
$2.7B
Q2 24
$2.9B
Total Debt
EMR
EMR
NXPI
NXPI
Q1 26
$11.7B
Q4 25
$7.6B
$11.0B
Q3 25
$8.9B
$11.0B
Q2 25
$8.3B
$9.5B
Q1 25
$8.2B
$10.2B
Q4 24
$6.6B
$10.4B
Q3 24
$7.7B
$9.7B
Q2 24
$7.1B
$9.7B
Stockholders' Equity
EMR
EMR
NXPI
NXPI
Q1 26
$10.9B
Q4 25
$20.3B
$10.1B
Q3 25
$20.3B
$10.0B
Q2 25
$19.9B
$9.6B
Q1 25
$19.2B
$9.3B
Q4 24
$20.5B
$9.2B
Q3 24
$21.6B
$9.4B
Q2 24
$20.8B
$9.0B
Total Assets
EMR
EMR
NXPI
NXPI
Q1 26
$27.1B
Q4 25
$41.9B
$26.6B
Q3 25
$42.0B
$26.4B
Q2 25
$42.5B
$25.3B
Q1 25
$42.0B
$25.2B
Q4 24
$42.6B
$24.4B
Q3 24
$44.2B
$23.7B
Q2 24
$45.6B
$23.2B
Debt / Equity
EMR
EMR
NXPI
NXPI
Q1 26
1.07×
Q4 25
0.37×
1.09×
Q3 25
0.44×
1.09×
Q2 25
0.42×
0.99×
Q1 25
0.42×
1.10×
Q4 24
0.32×
1.13×
Q3 24
0.36×
1.03×
Q2 24
0.34×
1.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EMR
EMR
NXPI
NXPI
Operating Cash FlowLast quarter
$699.0M
Free Cash FlowOCF − Capex
$602.0M
$714.0M
FCF MarginFCF / Revenue
13.9%
22.4%
Capex IntensityCapex / Revenue
2.2%
2.5%
Cash ConversionOCF / Net Profit
1.16×
TTM Free Cash FlowTrailing 4 quarters
$4.4B
$2.7B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EMR
EMR
NXPI
NXPI
Q1 26
Q4 25
$699.0M
$891.0M
Q3 25
$3.1B
$585.0M
Q2 25
$1.1B
$779.0M
Q1 25
$241.0M
$565.0M
Q4 24
$777.0M
$391.0M
Q3 24
$3.3B
$779.0M
Q2 24
$1.1B
$761.0M
Free Cash Flow
EMR
EMR
NXPI
NXPI
Q1 26
$714.0M
Q4 25
$602.0M
$793.0M
Q3 25
$2.7B
$508.0M
Q2 25
$977.0M
$696.0M
Q1 25
$154.0M
$426.0M
Q4 24
$694.0M
$261.0M
Q3 24
$2.9B
$593.0M
Q2 24
$998.0M
$576.0M
FCF Margin
EMR
EMR
NXPI
NXPI
Q1 26
22.4%
Q4 25
13.9%
23.8%
Q3 25
54.9%
16.0%
Q2 25
21.5%
23.8%
Q1 25
3.5%
15.0%
Q4 24
16.6%
8.4%
Q3 24
63.1%
18.2%
Q2 24
22.8%
18.4%
Capex Intensity
EMR
EMR
NXPI
NXPI
Q1 26
2.5%
Q4 25
2.2%
2.9%
Q3 25
8.9%
2.4%
Q2 25
2.0%
2.8%
Q1 25
2.0%
4.9%
Q4 24
2.0%
4.2%
Q3 24
9.1%
5.7%
Q2 24
2.1%
5.9%
Cash Conversion
EMR
EMR
NXPI
NXPI
Q1 26
Q4 25
1.16×
1.96×
Q3 25
4.86×
0.93×
Q2 25
1.83×
1.75×
Q1 25
0.50×
1.15×
Q4 24
1.33×
0.79×
Q3 24
3.35×
1.08×
Q2 24
3.31×
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EMR
EMR

Other$1.8B41%
Software And Systems$1.0B24%
Intelligent Devices$996.0M23%
Safety And Productivity$503.0M12%

NXPI
NXPI

Segment breakdown not available.

Related Comparisons